Where Immunogen Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have recently updated their ratings for Immunogen (NASDAQ:IMGN), with 6 analysts offering an average price target of $22.5, which is 39.32% higher than the current price of $16.15. The new average target represents an 8.85% increase from the previous target of $20.67. Over the past quarter, there have been 3 bullish, 1 somewhat bullish, and 2 indifferent ratings, with no bearish sentiments. Analysts typically review stocks quarterly or after major company events, basing their ratings on financial predictions and company performance.
November 20, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunogen's stock has received a higher average price target from analysts, suggesting a positive sentiment and a potential upside of 39.32% from the current price.
The increase in the average price target for IMGN, along with the predominantly bullish ratings from analysts, suggests a positive outlook for the stock. This could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100